Basilea Pharmaceutica announced new clinical and activity data for its antifungal drugs fosmanogepix and isavuconazole, as well as the antibiotic ceftobiprole, to be presented at IDWeek 2026 in Washington D.C. Highlights include pediatric data from fosmanogepix's Expanded Access Program and its effectiveness against Candida auris. These presentations reinforce Basilea's commitment to advancing treatments for serious fungal and bacterial infections, including unmet needs in pediatric care. The data presentations span oral talks and posters, showcasing ongoing research and clinical progress in these therapies.
Basilea's new clinical data presentations come as 81 of 150 priced Health-sector US stocks on Pluang rose today. For readers following Health stocks, here is Pluang's market snapshot as of Oct 20, 2026 13:11 WIB: Ionis Pharmaceuticals Inc. (IONS) traded at USD 44.39 with a 1-day change of +3.38% and a typical hold time of 5 days; Cassava Sciences Inc. (FLNA) was at USD 0.68, down 3.31%, with 100% buy order activity and a typical hold time of 38 days; Immunovant Inc. (IMVT) traded at USD 27.60, up 3.25%, with a typical hold time of 11 days.
Gainsight introduced its AI-native services business, Atlas, which manages over $75 million in annual recurring revenue (ARR) by handling long-tail customer renewals with AI agents and human managers. The company also announced a shift to value-based...
Owl Labs has introduced the Meeting Owl 5, a 4K UHD 360° teleconferencing camera designed for seamless hybrid meetings. It features a 20MP sensor, 360° fisheye lens, AI-powered audio with eight microphones, and an 18-foot voice pickup range. The devi...
Pulsar Helium Inc. announced a live "Ask Me Anything" session on October 27, 2026, where CEO Thomas Abraham-James and President Cliff Cain will answer investor questions in real time. The event aims to engage current and potential shareholders direct...
Equinor ASA announced it purchased 389,058 of its own shares on October 15, 2026, at an average price of NOK 429.24 per share as part of its ongoing buy-back program. The program, running from February 13, 2026, to January 15, 2027, aims to buy up to...
Equinor ASA has completed transactions under the third tranche of its 2026 share buy-back program, purchasing 540,275 shares between October 12 and 16 at an average price of NOK 425.48 per share. This tranche started on July 23 and will run until Oct...
